Golcadomide plus rituximab for relapsed follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug, Golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or hasn't responded to prior treatment. The goal is to see if this combination works better than other treatments your doctor might choose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have follicular lymphoma (grade 1, 2, or 3a) that has come back or hasn't responded to your last treatment.
- You must have had at least one prior treatment that included an anti-CD20 antibody (like rituximab) and a chemotherapy drug (like cyclophosphamide or bendamustine).
- You need to have a PET scan showing active lymphoma and a measurable tumor on CT.
- Your blood counts (neutrophils, platelets, and hemoglobin) must be at certain minimum levels.
- Your kidney function and liver function must be within acceptable ranges for the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether loncastuximab, combined with rituximab, can shrink and control follicular lymphoma that has come back or not responded to prior treatment. It may help people who still have active disease that needs treatment and meet specific scan and blood test requirements.
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
This trial tests a combination of radiation, an immunotherapy drug (tislelizumab), and chemotherapy (RCHOP) for people with previously untreated bulky follicular lymphoma. It aims to see if giving radiation first followed by the drug combo can improve outcomes for larger tumors.
This trial tests a combination of three drugs (tafasitamab, lenalidomide, and rituximab) for people with newly diagnosed follicular or marginal zone lymphoma who have not had treatment before. The goal is to see if this combination works well and is safe.
This trial tests a new combination of three drugs (golcadomide, poseltinib, and rituximab) for people with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. It may be an option if you cannot have a stem cell transplant.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.